Arrowstreet Capital Limited Partnership Increases Stake in Haleon PLC Sponsored ADR $HLN

Arrowstreet Capital Limited Partnership raised its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 82.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,674,518 shares of the company’s stock after purchasing an additional 6,647,329 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Haleon were worth $146,892,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Morgan Stanley raised its holdings in Haleon by 16.0% during the fourth quarter. Morgan Stanley now owns 21,495,383 shares of the company’s stock worth $217,318,000 after purchasing an additional 2,962,856 shares in the last quarter. Norges Bank purchased a new position in shares of Haleon during the fourth quarter worth about $163,529,000. Bank of America Corp DE lifted its holdings in shares of Haleon by 116.7% in the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after purchasing an additional 6,669,923 shares during the last quarter. Sculptor Capital LP increased its position in Haleon by 5.1% during the fourth quarter. Sculptor Capital LP now owns 10,454,868 shares of the company’s stock worth $105,699,000 after buying an additional 505,000 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in Haleon by 18.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 10,441,178 shares of the company’s stock worth $105,560,000 after buying an additional 1,589,494 shares during the period. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Up 0.9%

Shares of NYSE:HLN opened at $9.79 on Friday. The company has a market cap of $43.14 billion, a price-to-earnings ratio of 25.12, a PEG ratio of 2.26 and a beta of 0.13. Haleon PLC Sponsored ADR has a fifty-two week low of $8.65 and a fifty-two week high of $11.28. The firm’s 50-day simple moving average is $9.36 and its 200-day simple moving average is $9.85. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HLN. Zacks Research lowered shares of Haleon from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st. Rothschild & Co Redburn cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research note on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.